pluripotent stem cell News
-
NIH/NIDDK Phase II SBIR Awarded Sept 2015
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity ...
-
NIH/NIDDK Phase 1 SBIR Awarded July 2016
Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem ...
-
Kadimastem Granted a Patent in Israel for the Treatment of ALS
NESS ZIONA, ISRAEL, March 9, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis (ALS). Specifically, the patent allows for the innovative ...
-
Kadimastem Granted a Patent in Israel for the Treatment of ALS
NESS ZIONA, ISRAEL, March 9, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis (ALS). Specifically, the patent allows for the innovative ...
-
InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. Pluripotent stem cells have the ability to become any cell type of the adult body. The newly-released publication, entitled “Perspective: Why and How ...
-
Stem Pharm Awarded $1.7M NIH SBIR Grant for Better Models of the Brain
Stem Pharm has been awarded a $1.7 million SBIR grant from the National Institute of Environmental Health Sciences of the National Institutes of Health (NIH) to optimize its induced pluripotent stem cell (iPSC)-derived model of the central nervous system for drug discovery and toxicology applications. Stem Pharm’s model fills a commercial need to accurately reflect the complexity of cell ...
-
Neurona Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing restorative neural cell therapies to treat chronic neurological disorders, today announced that Cory Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, which is being held January 10 -13, 2022. The presentation will ...
-
TreeFrog Therapeutics expands Board with new independent members from the cell therapy industry
Elsy Boglioli, former Chief Operating Officer at French cell therapy biotech Cellectis, founder and Chief Executive Officer of biotechnology consulting practice Bio-Up, joins as Chair of the Board. Melissa Carpenter, PhD, Chief Scientific Officer of US-based cell & gene therapy biotech ElevateBio’s Regenerative Medicine unit, joins as independent board member. ...
-
Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes
Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use. ...
-
BlueRock Therapeutics Announces New Board Chair, New President and CEO
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?today?that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission ...
-
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference
Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies to treat chronic neurological disorders, today announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer will present a corporate overview at the Locust Walk Stem Cell Tx Conference, which is being organized in partnership with the Harvard Stem Cell Institute, ...
-
BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart ...
-
HORIBA announces the acquisition of the global assets of Photon Technology International, expanding its reach in the biomedical field.
HORIBA announces the acquisition of the global assets of Photon Technology International, Inc. and its affiliate companies (Photon Technology International or PTI). HORIBA Instruments Inc. (based in the U.S.) and other HORIBA Scientific group companies have acquired PTI’s worldwide business assets with the aim of increasing market share in fluorescence spectroscopy by taking advantage of ...
-
StemBioSys participates in Biotech Showcase Digital during J.P. Morgan Week 2021
StemBioSys, Inc., a privately held biomedical company that manufactures and develops innovative, advanced human stem cell technologies to improve the predictive power of pre-clinical drug safety screening, today announced its President and Chief Executive Officer Bob Hutchens will participate in Biotech Showcase Digital being held January 11-15, 2021. During Biotech ...
-
CGTLive Interview: New Frontiers in Allogeneic Cell Therapy
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
-
Leap forward in cell therapy manufacturing: data reveals highly reproducible stem cell expansion in 10L bioreactors, with exponential growth and preserved quality
Today, French cell therapy company TreeFrog Therapeutics released data showing the mass production of human induced pluripotent stem cells (hiPSC) produced with their proprietary C-Stem™ technology in 10L bioreactors at the 2021 Annual Meeting of the International Society for Stem Cell Research (ISSCR). The data shows the output from two batches with indistinguishable expansion ...
-
TreeFrog Therapeutics opens technological hub in Kobe, Japan, to drive partnerships opportunities in the field of iPSC-derived cell therapies
TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the incorporation of its Japanese subsidiary (KK) TreeFrog Therapeutics Japan and the establishment of a lab in Kobe, at the Creative Lab for Innovation Kobe (CLIK). Incorporated in Bordeaux, France, ...
-
Aelan collaborates with Gladstone Institutes to conduct comparative study on stem cells
San Francisco, CA - Aelan Cell Technologies today announced they have entered into an agreement with the Gladstone Institutes to further its studies on stem cell rejuvenation. This effort will be led by Meenakshi Gaur, Ph.D. of Aelan Cell Technologies and Kathryn Ivey, Ph.D. of the Gladstone Institutes. Aelan Cell Technologies will be conducting a comparative study that will involve ...
-
Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth
We are excited to announce that Gustav Mahler is hired as the Chief Executive Officer of Ncardia and Cellistic and will join the Board of Directors. Our founder Stefan Braam will assume the role of President and Chief Technical Officer and will remain in the board of directors. With this shift in our leadership team, we hope to continue our journey of rapid growth and expansion delivering world ...
-
Dr. Jeanne Loring Joins StemBioSys Scientific Advisory Board; World-renowned leader in Stem Cell Biology
Dr. Jeanne Loring, Professor Emeritus of The Scripps Research Institute, Founding Director of the Center for Regenerative Medicine at Scripps, and founder of Aspen Neuroscience, has joined the Scientific Advisory Board of StemBioSys, Inc., (SBS) a privately-held, San Antonio-based biomedical company focused on a broad range of cell-based products. StemBioSys CEO Bob Hutchens made the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you